Invesco Nasdaq Biotechnology ETF (NQ:IBBQ)

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

Topics ETFs

Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ ↗

September 02, 2026

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

Topics ETFs

Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket? ↗

August 22, 2026

Topics ETFs

uniQure Stock Tumbled 56% Today: What’s The FDA Angle? ↗

November 03, 2025

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a fraction of the cost.

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? ↗

August 21, 2026

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

Topics ETFs

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? ↗

August 19, 2026

Which Is the Better Invesco Healthcare ETF: Equal-Weight RSPH or Biotech-Focused IBBQ? ↗

Topics ETFs

August 12, 2026

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost.

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

Topics ETFs

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗

August 01, 2026

Better Healthcare Sector ETF: Vanguard's Broad VHT vs. Invesco's Biotechnology-Focused IBBQ ↗

Topics ETFs Intellectual Property

July 26, 2026

Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.

Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? ↗

Topics ETFs

July 22, 2026

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.

Topics ETFs

IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? ↗

July 18, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Topics ETFs

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.

Topics ETFs

Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? ↗

July 08, 2026

Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors.

Topics ETFs

Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗

June 04, 2026

AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.

Topics ETFs

Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗

November 24, 2025

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options ↗

November 20, 2025

Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally ↗

Topics Workforce

October 17, 2025

Wedbush’s new price target implies a whopping 730% potential upside to the stock’s closing price on Thursday.

Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ ↗

June 12, 2025

The company is also looking forward to a meeting with the FDA in early July to discuss a trial of Ryoncil in adults with steroid-refractory acute graft-versus-host disease.

Intutive Machines specializes in lunar missions and sophisticated space technologies. These ETFs are worth looking at.

These 4 ETFs Provide Smart Exposure To Intuitive Machines, The New Space Economy ↗

March 21, 2025

Via Benzinga

Topics ETFs

5 Undervalued ETFs To Ride On Powell's Market Optimism ↗

March 20, 2025

Here are five ETFs from different zones of the market that are currently undervalued and could generate solid returns in a rising stock market.

Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now ↗

Topics ETFs

January 23, 2025

A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Topics Artificial Intelligence

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch ↗

August 19, 2024

Via Benzinga

Topics ETFs

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A).

Biotech ETFs Pop On M&A Resurgence ↗

May 10, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Via MarketBeat

Topics ETFs

Should You Buy Biotech ETFs Now? ↗

June 16, 2021

Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and...